Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 5701 to 5715 of 7682 results

  1. Further data collection and research are recommended to assess the effectiveness of treatment options for bile acid diarrhoea. Consideration should be given to how well the treatments are tolerated and how they affect the severity of symptoms in the longer term.

    Recommendation ID DG44/03 Question Further data collection and research are recommended to assess the effectiveness of treatment options

    Research recommendation
    Published
    16 December 2021

  2. Further data collection and research are recommended to better understand the health-related quality of life in people with bile acid diarrhoea. Consideration should be given to how quality of life differs before and after a positive or negative test and diagnosis, and how it is affected by treatment and symptom severity.

    Recommendation ID DG44/04 Question Further data collection and research are recommended to better understand the health-related quality

    Research recommendation
    Published
    16 December 2021

  3. Further data collection and research are recommended to understand how SeHCAT (tauroselcholic [75 selenium] acid) test results affect clinical decision making.

    Recommendation ID DG44/01 Question Further data collection and research are recommended to understand how SeHCAT (tauroselcholic [75 selenium]

    Research recommendation
    Published
    16 December 2021

  4. Further data collection or research is recommended on the impact of implementing MRI fusion biopsy systems on the rate at which biopsies can be done, capacity resources and waiting times for this procedure.

    Recommendation ID DG53/2 Question Further data collection or research is recommended on the impact of implementing MRI fusion biopsy systems

    Research recommendation
    Published
    11 July 2023

  5. Further diagnostic accuracy studies, or analyses of existing data sets, are recommended to assess the accuracy of the tests included in this assessment in the following subgroups:- people who are premenopausal- people who are postmenopausal- people with suspected early stage ovarian cancer, that is, disease apparently confined to the pelvis.Future studies should be done in populations that are representative of people with suspected ovarian cancer who are assessed in NHS secondary care.

    Recommendation ID DG31/1 Question Further diagnostic accuracy studies, or analyses of existing data sets, are recommended to assess the

    Research recommendation
    Published
    18 October 2018

  6. Further good quality evidence is needed to address uncertainties about myCOPD's clinical benefits and its effect on healthcare resource use. myCOPD has potential for clinical benefits, but more evidence is needed to reduce uncertainties. The committee considered that comparative evidence is needed to show the clinical benefits of using myCOPD in 2 populations: people using it to self-manage COPD people referred to pulmonary rehabilitation For self-management, a randomised controlled trial is preferred to show the clinical benefits of myCOPD. This could be powered based on the encouraging results in the RESCUE study. However, a high-quality comparative observational study designed to minimise bias in the results may provide acceptable evidence. Outcomes such as rates of exacerbations, hospital readmissions and unscheduled care appointments should be considered alongside patient-reported outcomes such as health-related quality of life. For pulmonary rehabilitation, further evidence is needed to show the clinical benefits of myCOPD. This could be a randomised controlled trial which is powered based on the encouraging results in the TROOPER study or a well-designed comparative observational study. Key outcomes will be the CAT score and 6-minute walk test, ideally supported by additional longer-term outcomes such as rates of exacerbations and hospital admissions. Real-world data could be used to inform the uptake rates in the economic modelling. It should also include qualitative data on patient experience using myCOPD such as patient preferences and adherence.

    Recommendation ID MTG68/01 Question Further good quality evidence is needed to address uncertainties about myCOPD's clinical benefits and

    Research recommendation
    Published
    8 April 2022

  7. A randomised controlled trial is recommended to compare DyeVert Systems  with standard care. The aim of this research would be to address uncertainties  about whether using DyeVert Systems reduces AKI incidence and rate of renal  replacement therapy after using contrast media. This must include people with  stage 4 chronic kidney disease (with an estimated glomerular filtration rate  [eGFR] under 30 ml/min/1.73 m 2 ), who are at risk of AKI and need elective  coronary or peripheral angiography.

    Recommendation ID MTG60/01 Question A randomised controlled trial is recommended to compare DyeVert Systems with standard care. The aim

    Research recommendation
    Published
    5 November 2021

  8. Further primary research is recommended on the clinical effectiveness of using ELISA tests for therapeutic monitoring of TNF‑alpha inhibitors in people with rheumatoid arthritis.

    Recommendation ID DG36/1 Question Further primary research is recommended on the clinical effectiveness of using ELISA tests for therapeutic

    Research recommendation
    Published
    25 October 2019

  9. Further research and publication of observational data would be useful. Publications should describe details of patient selection, particularly in relation to previous treatments. They should also describe clinical outcomes (including all complications) and patient experience in the longer term. NICE may review the procedure on publication of further evidence.

    Recommendation ID IPG439/1 Question Further research and publication of observational data would be useful. Publications should describe

    Research recommendation
    Published
    9 June 2015

  10. Further research designed to investigate differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior taxane exposure, would be particularly useful.

    Recommendation ID TA214/1 Question Further research designed to investigate differences in health-related quality of life and the clinical

    Research recommendation
    Published
    9 June 2015

  11. What is the health impact of exposure to individual air pollutants alone or combined with each other in the home?

    Recommendation ID NG149/1 Question What is the health impact of exposure to individual air pollutants alone or combined with each other

    Research recommendation
    Published
    10 February 2020

  12. What are the service and service user characteristics of highly specialist and longer-term high-dependency rehabilitation units that are associated with better outcomes?

    Recommendation ID NG181/3 Question What are the service and service user characteristics of highly specialist and longer-term high-dependency

    Research recommendation
    Published
    26 October 2020

  13. Herbal medicines:- Are Chinese and non-Chinese herbal medicines safe and effective as first-line therapy in the treatment of [Irritable bowel syndrome] (IBS), and which is the most effective and safe option?

    Recommendation ID CG61/5 Question Herbal medicines:- Are Chinese and non-Chinese herbal medicines safe and effective as first-line therapy

    Research recommendation
    Published
    9 June 2015

  14. What is the effectiveness of hormone-modifying agents in the treatment of acne vulgaris?

    Recommendation ID NG198/8 Question What is the effectiveness of hormone-modifying agents in the treatment of acne vulgaris? Any explanatory

    Research recommendation
    Published
    3 May 2024

  15. Acceptability of drug misuse prevention interventions:- How acceptable are drug misuse prevention interventions among groups vulnerable to drug misuse in the UK? How acceptable are drug misuse prevention interventions among practitioners in the UK? How can acceptability be improved for groups that are vulnerable to drug misuse and practitioners?

    Recommendation ID NG64/4 Question Acceptability of drug misuse prevention interventions:- How acceptable are drug misuse prevention interventions

    Research recommendation
    Published
    4 May 2017